There are 2137 resources available
631P - Darolutamide (D), enzalutamide (E) and apalutamide (A), the risk of adverse events (AEs) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC): Number needed to harm (NNH)
Presenter: Daniel George
Session: E-Poster Display
Resources:
Abstract
632P - Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic castration-resistant prostate cancer (nmCRPC) receiving androgen deprivation therapy (ADT)
Presenter: Stephane Oudard
Session: E-Poster Display
Resources:
Abstract
633P - Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III ARAMIS trial
Presenter: Karim Fizazi
Session: E-Poster Display
Resources:
Abstract
634P - Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison” of the STAMPEDE trial
Presenter: Aine Haran
Session: E-Poster Display
Resources:
Abstract
635P - ARCHES - The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of efficacy by baseline prostate-specific antigen (PSA) levels
Presenter: Antonio Alcaraz
Session: E-Poster Display
Resources:
Abstract
636P - A study of sustained androgen signaling dependence in metastatic castrate resistant prostate cancer (mCRPC)
Presenter: Myrto Boukovala
Session: E-Poster Display
Resources:
Abstract
637P - The prognostic value of the baseline neutrophil-to-lymphocyte ratio (NLR) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving radium-223 (Ra-223): A post-hoc analysis of the ALSYMPCA phase-III trial
Presenter: Alexander Meisel
Session: E-Poster Display
Resources:
Abstract
638P - Meningeal metastases (MM) in patients with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Mihaela Aldea
Session: E-Poster Display
Resources:
Abstract
639P - 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide
Presenter: Joan Carles
Session: E-Poster Display
Resources:
Abstract
640P - Quality of life and survival in elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts) treated with docetaxel
Presenter: Irene Paredero Perez
Session: E-Poster Display
Resources:
Abstract